DekaBank Deutsche Girozentrale
ZVRA icon

DekaBank Deutsche Girozentrale’s Zevra Therapeutics ZVRA Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-413
Closed -$99K – 1050
2016
Q1 		$99K Buy
+413
New +$100K ﹤0.01% 962

Other funds holding ZVRA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ZVRA Position: Q2 2016 in Review

DekaBank Deutsche Girozentrale sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 413 shares — an estimated $99K sold.

DekaBank Deutsche Girozentrale first reported a position in ZVRA in Q1 2016 and held it in 1 quarter. The position peaked at $99K in Q1 2016. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • DekaBank Deutsche Girozentrale reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 413 Zevra Therapeutics shares in Q2 2016, an estimated $99K.
  • DekaBank Deutsche Girozentrale first reported a position in Zevra Therapeutics in Q1 2016 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's Zevra Therapeutics position peaked at $99K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2016, filed 4 Aug 2016.